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Some cancers treated with allogeneic hematopoietic stem cell transplantation (HSCT) are sensitive to natural
killer cell (NK) reactivity. NK function depends on activating and inhibitory receptors and is modiﬁed by NK
education/licensing effect andmediated by coexpression of inhibitory killer-cell immunoglobulin-like receptor
(KIR) and its corresponding HLA I ligand. We assessed activating KIR (aKIR)-based HLA Iedependent education
capacity in donor NKs in 285 patients with hematological malignancies after HSCT from unrelated donors. We
found signiﬁcantly adverse progression-free survival (PFS) and time to progression (TTP) in patients who
received transplant from donors with NKs educated by C1:KIR2DS2/3, C2:KIR2DS1, or Bw4:KIR3DS1 pairs (for
PFS: hazard ratio [HR],1.70; P¼ .0020, Pcorr¼ .0039; HR,1.54; P¼ .020, Pcorr¼ .039; HR,1.51; P¼ .020, Pcorr¼ .040;
and for TTP: HR, 1.82; P ¼ .049, Pcorr ¼ .096; HR, 1.72; P ¼ .096, Pcorr ¼ .18; and HR, 1.65; P ¼ .11, Pcorr ¼ .20,
respectively). Reduced PFS and TTP were signiﬁcantly dependent on the number of aKIR-based education
systems in donors (HR,1.36; P¼ .00031, Pcorr¼ .00062; and HR,1.43; P¼ .019, Pcorr¼ .038). Furthermore, the PFS
and TTP were strongly adverse in patients with missing HLA ligand cognate with educating aKIR-HLA pair in
donor (HR, 3.25; P ¼ .00022, Pcorr ¼ .00045; and HR, 3.82; P ¼ .027, Pcorr ¼ .054). Together, these data suggestdgments on page 838.
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J. Nowak et al. / Biol Blood Marrow Transplant 21 (2015) 829e839830important qualitative and quantitative role of donor NK education via aKIR-cognate HLA ligand pairs in the
outcome of HSCT. Avoiding the selection of transplant donors with high numbers of aKIR-HLA-based education
systems, especially for recipients with missing cognate ligand, is advisable.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Natural killer (NK) cells are critical to the innate immune
system because they mediate cytotoxic lysis to cancer and
virally infected cells [1,2]. In hematopoietic stem/progenitor
cell transplantation (HSCT), NK cells play an important role
mediating the graft-versus-tumor (GVT) effect [3-7]. Among
NK cell receptors, inhibitory killer cell immunoglobulin-like
receptors (iKIRs) are of paramount importance because of
their ability to recognize ubiquitously expressed host major
histocompatibility complex (MHC) class I ligands [8,9] and
their regulatory role due to NK cell education or licensing
[10]. Apparently, the extracellular domains of some acti-
vating killer cell immunoglobulin-like receptors (aKIRs),
such as KIR2DS1-4 and KIR3DS1, are highly homologous to
their inhibitory counterparts, probably resulting from both
the evolution by gene duplication [11] and functional selec-
tion. Moreover, the ligation capacity of these activating KIRs
and HLA class I ligands has been suggested [8,12]. Despite
this homology and ligation to HLA class I, the functionality of
aKIRs is not fully assessed, considering their relatively low
afﬁnity to the cognate MHC class I ligands [13] and assumed
negligible functionality in allo-HSCT. Indeed, except KIR2DS1,
which has been shown to interact in education fashion with
group 2 HLA-C molecules (C2 group) in vitro and in HSCT
settings [14,15], no further functional effects were demon-
strated between interacting aKIRs and HLA class I molecules.
HLA class I mismatch between hematopoietic stem/pro-
genitor cells (HSC) in the donor and recipient may lead to
“missing self” recognition, deﬁned as the NK cell’s capacity to
attack allogeneic cells when an HSC donor-recipient pair is
MHC class I mismatched [16-18]. This hypothesis assumes
that NK cells expressing iKIR cannot be inhibited if the
cognate HLA class I ligand is missing or extinguished from
target cells. However, some subsets of NK cells lack all known
self-MHCespeciﬁc inhibitory receptors, yet they are never-
theless self-tolerant [19]. The lack of data on potential role of
aKIRs in HSCT prevented their incorporation into the current
hypothesis explaining NK cell allorecognition, including the
“missing self” recognition model.
It is well established that NK cell inhibition mediated by
iKIRs is overseen by the NK cell licensing, mediated by the
coexpression of iKIR and its cognate self MHC class I ligand
[10,20]. Through the licensing process, only licensed NK cells
become fully competent to be triggered through activating
receptors, while remaining tolerant to the normal tissues
[21,22]. This observation implies that mature NK cell subsets
of different killing potential are present in a host depending
on stochastic expression of iKIRs and the speciﬁcity of ubiq-
uitously expressed HLA ligands. Support for a mirroring role
of activating KIRs in NK cell education was demonstrated in
an in vitro study where freshly isolated NK cells from donors
coexpressing KIR2DS1 andHLA-C2 in homozygous dosewere
hyporesponsive to cellular targets [23]. In clinical HSCT for
patients with acute myeloid leukemia, it was demonstrated
that coexpression of activating KIR2DS1with homozygous C2
ligand in the donor did not provide any antileukemic effect,
compared with C1 expressing donors [15], indicatinghyporesponsiveness of C2/C2:KIR2DS1 coexpressing NK cells
in HSCT setting. Thus, although the idea of the NK cell edu-
cation function of C2:KIR2DS1 system was supported, it re-
mains elusive for other aKIR genes speciﬁc for self-MHC class
I. It seems unlikely that the killing capacity of those highly
active educated NK cells can be assessed by the association
study with only 1 KIR or HLA genetic system considered.
Using a model of germline-encoded activating KIRs and
their cognate self MHC class I ligand gene pairs in HSC do-
nors, we investigated whether the NK cell expression of
different activating KIRs in the presence of their cognate HLA
ligands in donors could affect the clinical outcome in patients
with malignant diseases who underwent HSCT. Subse-
quently, we assessed a potential dose effect of the aKIR-HLA
ligand systems in donors, in terms of education capacity and
the clinical effect of missing single educating HLA ligand in
HSC recipients.
METHODS
Patients and Donors
We evaluated 285 patients with lympho- and myeloproliferative ma-
lignancies who received HSC between 2002 and 2010 from unrelated donors
matched for 7 to 10 of the possible 10 alleles at HLA-A, -B, -C, -DRB1, and
-DQB1 loci. HLA genotyping data at allele level were provided and veriﬁed
by the Lower Silesian Center for Cellular Transplantationwith National Bone
Marrow Donor Registry, Institute of Hematology and Transfusion Medicine,
and Medical University of Warsaw search centers. Transplantations were
facilitated and clinical data and informed consent from the patients were
provided by the 9 clinical transplantation centers mentioned in the afﬁlia-
tions. All of the transplantation centers were active European Group for
Blood and Marrow Transplantation member teams [24] and adhered to the
contemporary European Group for Blood and Marrow Transplantation
practice guidelines and recommendations for HSCT procedures. The study
was approved by the Wroclaw Medical University ethics committee.
Characteristics of Patients and Donors
Characteristics of the 285 patients with malignant diseases and their
donors are listed in Table 1. We compared 2 groups of patients: those with
and without aKIR-HLA I ligand education systems. Patient groups were
similar with respect to age, diagnosis, risk level, year of transplantation,
conditioning regimen, graft-versus-host disease (GVHD) prophylaxis, do-
nor’s ethnic group, graft type, degree of HLA matching, and class of HLA
mismatch. Patient groups whose donors were sufﬁcient or devoid of aKIR-
HLA education systems and those patients with and without HLA ligand
for aKIR-HLA education system in donors were evaluated for HSCT outcome
and the incidence of acute GVHD (aGVHD) grade II to IV.
KIR Genotyping Method
KIR genotyping was performed on genomic DNA from unrelated HSC
donors with the use of PCR ampliﬁcation with sequence-speciﬁc primers.
KIR genotyping kit (Inno-Train Diagnostik GmbH, Kronberg, Germany) was
used according to the manufacturer’s protocol, with minor modiﬁcations as
detailed previously [25]. Twelve blind samples were KIR retyped for quality
control and the results were consistent with primary data.
KIR-ligand Groups and NK Cell Licensing Systems
Regular association study of KIRs or their HLA ligand groups is insufﬁ-
cient to assess the educated NK cells that are likely be more responsive,
compared with uneducated NK cells. The novelty of this model of
association study depends on 2 level assignments of each donor according to
(1) aKIR gene speciﬁcity, and (2) cognate HLA class I ligand group (2-level-
selection). This assignment can give an insight into potential aKIR-based NK
cell education capacity. Further, 3-level-selection according to (1) aKIR gene
speciﬁcity, (2) cognate HLA class I ligand group in the donor, and (3) HLA
class I ligand group in the recipient can give an insight in potential role of
Table 1
Characteristics of Patients with Malignant Diseases and Stem-Cell Donors,
according to the HLA-aKIR Education Capacity in Donor (N ¼ 285)
Characteristic HLA-aKIR Education Capacity in Donor
Present
(n ¼ 240)
Deﬁcient
(n ¼ 45)
P
Patient age, median
(range), yr
31.7 (1.6-59.5) 28.5 (3.4-55.7) .56
Diagnosis
AML 114 (48) 19 (42) .13
ALL (including BCR-
ABL positive)
57 (24) 12 (27)
Acute leukemia
(unspeciﬁed)
5 (2) 1 (2)
Chronic leukemia 51 (21) 10 (22)
Lymphoma 6 (3) 3 (7)
Multiple myeloma 7 (3) 0
Risk level at time of
transplantation*
High 50 (21) 6 (13) .12
Intermediate 45 (19) 7 (16)
Low 126 (53) 30 (67)
Missing data 19 (8) 2 (4)
Year of transplantation
2002-2007 113 (47) 27 (60) .11
2008-2010 127 (53) 18 (40)
Conditioning regimen
Myeloablative 145 (60) 29 (64) .23
Reduced intensity 84 (35) 12 (27)
Missing data 11 (5) 4 (9)
GVHD prophylaxis
Cyclosporine 196 (82) 38 (84) .19
Methotrexate 102 (43) 19 (42)
T cell depletion 39 (16) 8 (18)
Other 10 (4) 1 (2)
Ethnic group of donory
Polish 50 (21) 8 (18) .64
Other European 190 (79) 37 (82)
Source of stem cells
Bone marrow 58 (24) 13 (29) .30
Peripheral blood 171 (71) 31 (69)
Missing data 11 (5) 1 (2)
Degree of HLA matching
10 of 10 alleles matched 158 (66) 36 (80) .26
9 of 10 alleles matched 65 (27) 8 (18)
8 of 10 alleles matched 16 (7) 1 (2)
7 of 10 alleles matched 1 (<1) 0
Class of HLA mismatch
Class I 62 (26) 7 (16) .30
Class II 14 (6) 2 (4)
Class I and II 6 (3) 0
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BCR-ABL,
breakpoint cluster region-Abl 1 (Abelson) fusion gene.
Data presented are n (%) unless otherwise indicated. Present denotes
presence of at least 1 aKIR-based HLA ligand-mediated NK cell education
system in donor. Deﬁcient denotes aKIR-null donors.
* Low risk indicates ﬁrst complete remission or chronic phase; interme-
diate risk, second or higher complete remission or chronic phase; and high
risk, primary induction failure, relapse or progression.
y All patients reported ethnic group of European Polish ancestry.
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in recipients. Speciﬁcally, analogous to iKIR-based NK cell licensing, the lack
of this particular HLA ligand in the recipient may be potentially associated
with “downward resetting” of aKIR-based education [26]. Alleles of HLA-A,-
B, and-C loci were assigned to 4 aKIR-ligating groups (C1, C2, Bw4, and A11/
C2/4/5/16), according to 77 to 83 amino acid residue sequence of the HLA
class I heavy chain [27], as listed by Dorak [28] and Graef et al. [12]. Because
inhibitory function of those infrequent HLA-A alleles with Bw4 epitope was
proven, they were incorporated into the Bw4-activating KIR ligand group
[29]. NK cell education status was deﬁned as discovery of germline-encoded
and potentially coexpressed aKIR and its self MHC I ligand gene pair in a
donor. By analogy to experimental data for iKIRs, we assessed the clinical
role of NK cell subsets educated via aKIR-HLA pairs in such donors [14,23].
Functional cognate HLA-aKIR gene pairs were assigned according to the
classiﬁcation described by Long and Rajagopalan [8] and Graef et al. [12],who described ligation capacity of these receptors and ligands. Generally,
the following 4 HLA-aKIR cognate gene pair types (aKIR-based NK cell ed-
ucation systems) were assigned in different donors in different combina-
tions: C1:KIR2DS2 and/or C1:KIR2DS3 (C1:KIR2DS2/3), C2:KIR2DS1,
Bw4:KIR3DS1, and A11/C2/4/5/16:KIR2DS4 (2-level-selection). In HLA class
Iemismatched donor-recipient pairs, the status of patients missing HLA
ligands cognate with donors’ aKIR-educated NK cells was established (3-
level-selection) and clinical outcomes were compared with that of pa-
tients with the HLA ligand.
Statistical Analysis
Cox regressionwas used to examine the hazard ratios of failure for time-
to-event outcomes of HSCT (progression-free survival [PFS] and time to
progression [TTP]) with HLA-aKIR education status in donor. Failure for PFS
was deﬁned as relapse, progression, or death, whichever occurred ﬁrst. TTP
was deﬁned as time to relapse or progression. Relapse was deﬁned as he-
matological, cytological, or molecular relapse, whichever was diagnosed
ﬁrst, of acute leukemia in complete remission or chronic leukemia in chronic
phase. Progression was deﬁned as progression to more advanced stage of
malignant disease without complete remission or chronic phase at trans-
plantation. Logistic regression was used to assess the association of donor
aKIR-HLA education status with the probability of aGVHD grade II to IV.
Wherever possible, models were adjusted for the patient’s age, diagnosis,
level of risk (low or intermediate/high), and conditioning regimen (mye-
loablative or reduced-intensity conditioning). As we have analyzed similar
data as iKIR-based NK cell licensing in the prior publication [30], adjust-
ments were made for multiple comparisons using the Bonferroni inequality
method, according to the formula Pcorr ¼ 1(1P)k, where k equals the
number of comparisons. Estimates of PFS were obtained with the Kaplan-
Meier method, and cumulative incidence estimates were used to summa-
rize the probability of time-to-event outcomes. Death without relapse or
progressionwas regarded as a competing risk for purposes of estimating the
TTP. Statistics were estimated and Kaplan-Meier survival analyses were
made using Statistica 9.1 package (StatSoft, Tulsa, OK).
RESULTS
Distribution of aKIR-based NK Cell Education Systems
To assess aKIR-HLAemediated education in clinical
transplantation, we ﬁrst evaluated the distribution of HLA
ligand-aKIR-based education systems in 285 transplant do-
nors for patients with malignant diseases. The frequencies of
HLA class I ligand groups and aKIR genes in the patients were
consistent with gene frequencies in previously published
studies [31,32]. The majority of donors (n ¼ 240, 84%)
encoded from 1 to 4 putative aKIR-HLA education systems
(C1:KIR2DS2/3, C2:KIR2DS1, Bw4:KIR3DS1, and/or A11/C2/4/
5/16:KIR2DS4 systems) (Table 2). However, in 45 (16%) do-
nors (aKIR-HLA null donors) the HLA-Ae, Be, and
Cedependent aKIR-based education systems were not
detected. In 113 (40%) donors, a single aKIR education system
was revealed, and in the remaining 128 (44%) donors, 2 or
more systems overlapped. The level of overlapping is char-
acterized in Table 2.
aKIR-based Education Systems in Donor and Clinical
Outcome
To clarify the contribution of different aKIRs to the HLA-
ligand dependent functionality in NK cell education, we
compared PFS and TTP in HSCT recipients who underwent
transplantation from donors with coexpression of aKIR and
cognate HLA ligand versus recipients who underwent
transplantation from donors without a corresponding aKIR-
based education system. We found a signiﬁcantly reduced
PFS and increased rate of progression, estimated as TTP, in
patients who underwent transplantation from donors who
coexpressed C1:KIR2DS2/3 molecules, compared with pa-
tients who underwent transplantation from donors negative
for C1-based system (42.4% versus 56.9%; hazard ratio [HR],
1.70; 95% conﬁdence interval [CI], 1.22 to 2.38; P ¼ .0020,
Pcorr ¼ .0039; median time to event, 185.5 versus 421 days;
Table 2
Distribution of HLA-aKIRebased Education Systems in Donors for Patients
who Underwent Transplantation with Malignant Diseases (N ¼ 285)
HLA-aKIRebased Education Systems in Donors Distribution
Presence of aKIR-HLA-based education systems
C1:KIR2DS2 or C1:KIR2DS3, n (%) 137 (48)
C2:KIR2DS1, n (%) 71 (25)
Bw4:KIR3DS1, n (%) 88 (31)
A11/C2/4/5/16:KIR2DS4, n (%) 137 (48)
Number of aKIR-HLA based
education systems, n (%)
0 45 (16)
1 113 (40)
2 78 (27)
3 32 (11)
4 17 (6)
Overlapping of aKIR-HLA based
education systems, no./n (%)
C1:KIR2DS2 or C1:KIR2DS3, no./n (%)
Single 41/137 (30)
Overlapped 96/137 (70)
C2:KIR2DS1, no./n (%)
Single 3/71 (4)
Overlapped 68/71 (96)
Bw4:KIR3DS1, no./n (%)
Single 8/88 (9)
Overlapped 80/88 (91)
A11/C2/4/5/16:KIR2DS4, no./n (%)
Single 60/137 (44)
Overlapped 77/137 (56)
Total, no./n (%)
Single 113/240 (47)
Overlapped 127/240 (53)
At least 1 of C1 and C2 education systems 169/285 (59)
At least 1 out of C1, C2 and Bw4
education systems
179/285 (63)
At least 1 of C1, C2, Bw4 and
A11/C2/4/5/16 education systems
240/285 (84)
Education systemdenote coexpressionof C1andKIR2DS2orKIR2DS3, C2and
KIR2DS1, Bw4 and KIR3DS1, or A11/C2/4/5/16 and KIR2DS4 genes in donor.
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.049, Pcorr ¼ .096; median time to event, 186 versus 402.5
days; for PFS and TTP, respectively) (Figure 1A,B). Similarly,
signiﬁcantly reduced PFS and TTP were found for
C2:KIR2DS1 and Bw4:KIR3DS1 systems in donors (39.7%
versus 53.6%; HR, 1.54; 95% CI: 1.07 to 2.23; P ¼ .020, Pcorr ¼
.039; median time to event, 173.5 versus 356 days; and 23.3%
versus 16.5%; HR,1.72; 95% CI, .91 to 3.24; P¼ .096, Pcorr¼ .18;
median time to event, 176.5 versus 351 days; for C2:KIR2DS1
system, respectively; and 40.5% versus 54.4%; HR, 1.51; 95%
CI, 1.07 to 2.14; P ¼ .020, Pcorr ¼ .040; median time to event,
183.5 versus 359 days; and 27.7% versus 16.2%; HR, 1.65, 95%
CI, .90 to 3.02; P ¼ .11, Pcorr ¼ .20; median time to event, 199
versus 356 days; for Bw4:KIR3DS1 system, respectively)
(Figure 1C-F). These results suggest functionality of
C1:KIR2DS2/3, C2:KIR2DS1, and Bw4:KIR3DS1 aKIR-
HLAebased systems in education of NK cells. The adverse
clinical outcomes in patients with malignancy who under-
went HSCT suggests that NK cells educated by these systems
are hyporesponsive against tumors. However, for patients
who underwent transplantation from A11/C2/4/5/
16:KIR2DS4-positive donors, the clinical outcome was
similar to patients with donors negative for this system
(48.1% versus 52.1%; HR, 1.03; 95% CI .74 to 1.44; P ¼ .85,
Pcorr ¼ .96; median time to event, 335 versus 292.5 days; and
21.7% versus 15.0%; HR, 1.43; 95% CI, .78 to 2.59; P ¼ .24,
Pcorr ¼ .43; median time to event, 297 versus 349 days; for
PFS and TTP, respectively in patients with and without A11/
C2/4/5/16:KIR2DS4 system in donor) (Figure 1G,H).Quantity of aKIR-based Education Systems
Given the overlapping of different aKIR-HLA education
systems (from 0 to 4 systems in a donor) (Table 2), we sought
to determine whether the number of the aKIR-based educa-
tion systems in the donor affected the clinical outcome in
HSCT recipients. We found highly signiﬁcantly reduced PFS
and TTP with an increasing number of aKIR-based education
systems. For 0 to 2 systems in a donor (including C1:KIR2DS2/
3 and C2:KIR2DS1 systems) we found decreasedmedian time
to event being highly associated with increased number of
systems (median time to event: 463, 218, and 157.5 days; HR,
1.60; 95% CI, 1.26 to 2.04; P ¼ .00013, Pcorr ¼ .00026; and me-
dian time to event, 421, 225, and 157.5 days; HR, 1.76; 95% CI,
1.15 to 2.70; P ¼ .0098, Pcorr ¼ .019; for PFS and TTP, respec-
tively) (Figure 2A,B). For 0 to 3 aKIR-based systems in a donor
(including C1:KIR2DS2/3, C2:KIR2DS1, and Bw4:KIR3DS1
systems), the PFS and TTPwere similarly adversely associated
with the number of aKIR-based education systems in donor
(HR, 1.36; P ¼ .00031, Pcorr ¼ .00062; and HR, 1.43; P ¼ .019,
Pcorr¼ .038; for PFS and TTP, respectively) (Figure 2C,D). These
data suggest that coexpression of multiple aKIRs and cognate
HLA ligands in donors (education system overlapping) can
increase the tolerization of antitumor NK cell subsets and
worsen the clinical course in quantitative manner.
We did not ﬁnd a difference in clinical outcome among
malignant patients after HSCT from aKIR-expressing donors
with homozygous or heterozygous cognate HLA ligand
background (data not shown).
Quality of aKIR-based Education System
To assess qualitative variability among different education
systems, we compared clinical outcomes in patients who
underwent transplantation from aKIR-HLA null donors to
those with single positive (sp) C1:KIR2DS2/3 and spA11/C2/
4/5/16:KIR2DS4 donors when bias from overlapping systems
in donors was excluded. Given that HLA-C*02, C*04, and C*05
molecules (but not A*11 and C*16 molecules) potentially
ligate both KIR2DS4 and KIR2DS1 (receptor for C2 group)
[8,12] andmight produce a partial functional overlapping, we
excluded donor-recipient pairs with C2:KIR2DS1-positive
donors from the comparison. Additionally, patients who
underwent transplantation from donors positive for HLA-
C*16:01, a member of C1 group, were excluded to avoid po-
tential partial overlapping between KIR2DS4- and KIR2DS2/
3-based NK cell education. In this comparison, the bias of
overlapping systems was reduced as far as possible, and a
role of spC1- and spA11/C2/4/5-based aKIR education was
compared with patients who underwent transplantation
from aKIR-HLA null donors. In patients who underwent
transplantation from donors with spC1:KIR2DS2/3, the PFS
was the adverse of that of patients who underwent trans-
plantation from aKIR-null and spA11/C2/4/5-KIR2DS4-
positive donors, but these differences were of limited
signiﬁcance (51.2%, 55.6%, and 68.4%; median time to event,
359, 365, and 553 days; HR, .86; 95% CI, .75 to 1.00; P ¼ .052,
Pcorr¼ .10; for spC1:KIR2DS2/3, aKIR-HLA null, and spA11/C2/
4/5-KIR2DS4 systems, respectively) (Figure 3A). For TTP, the
differences were insigniﬁcant (16.7%, 7.7%, and 12.5%; me-
dian time to event, 357.5, 348, and 522.5 days; HR, .99; 95%
CI, .75 to 1.31; P¼ .93, Pcorr ¼ 1.00; for spC1:KIR2DS2/3, aKIR-
null, and spA11/C2/4/5-KIR2DS4 systems, respectively)
(Figure 3B). These outcomes may indicate the low education
capacity of single aKIR-HLAebased system and are in line
with quantitative role ofmultiple systems. Likely, the A11/C2/
4/5-KIR2DS4 system is weakly involved in NK cell education.
Figure 1. Clinical outcome in transplant recipients with malignant diseases depending on activating KIR-cognate HLA ligand-mediated NK cell education in donor.
The cumulative PFS (left panels) and TTP (right panels) are shown for patients with (A,B) C1:KIR2DS2/3, (C,D) C2:KIR2DS1, (E,F) Bw4:KIR3DS1, and (G,H) A11/C2/4/5/
16:KIR2DS4 NK cell education systems in donors, compared with patients whose donors were deﬁcient with the corresponding system. D(þ) denotes positive in
donor; D(), negative in donor. Pcorr denotes P value corrected using Bonferroni inequality method according to the formula Pcorr ¼ 1(1P)k where k equals the
number of comparisons.
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KIR2DS4 activating receptor or its lowafﬁnity to cognate HLA
ligands [12,33-35], as discussed further.aKIR-based NK Cell Education Effect was Not Associated
with HLA Disparity and aGVHD
To evaluate a potential bias from HLA mismatch that
alone may inﬂuence the clinical outcome in HSC recipients,
we compared the PFS and TTP in patients who underwent
transplantation from donors with and without aKIR-
HLAebased education system when the study group was
restricted to HLA-mismatched donor-recipient pairs. As in
the total group, the PFS and TTP of the corrected group
remained adverse upon aKIR-based education in donors,
suggesting no inﬂuence of the HLA mismatch itself (Table 3).
Additionally, a kind of hierarchy of the clinical effect was
conﬁrmed in this comparison, with the adverse effect
becoming weaker, starting from C1:KIR2DS2/3 through
C2:KIR2DS1 and Bw4:KIR3DS1 to A11/C2/4/5/16:KIR2DS4
system (for PFS, from HR, 3.17, P¼ .00024, Pcorr¼ .00048; HR,
2.03; P ¼ .021, Pcorr ¼ .042; HR, 1.89, P ¼ 034, Pcorr ¼ .067; to
HR, .84; P¼ .57, Pcorr¼ .82, respectively; and for TTP, fromHR,
5.97; P¼ .0071, Pcorr¼ .014; HR, 2.82; P¼ .065, Pcorr¼ .13; HR,
1.73; P ¼ .34, Pcorr ¼ .56; to HR, .85, P ¼ .77, Pcorr ¼ .95,
respectively) (Table 3). By this hierarchy, a qualitative
variability of aKIR-based education systems seems to be
supported.To assess the involvement of the acute GVHD (the major
factor of morbidity and mortality in HSCT) in the clinical
outcome in patients with aKIR-HLAemediated NK cell edu-
cation, we compared the incidence of grade II to IV aGVHD in
patients who underwent transplantation from donors with
and without an aKIR-based education systems. No signiﬁcant
associations of aGVHD grade II to IV were found in patients
whose donors were sufﬁcient versus deﬁcient with either of
an aKIR-based education system tested (for detailed results
see, Table 4). These results suggest that clinical effects in
patients who received a transplant from donors with an
aKIR-HLAebased educated NK cells were independent of the
degree of HLA matching and not associated with the inci-
dence of aGVHD of intermediate/high grade.
Missing Patient HLA Ligand for Donor aKIR-HLAebased
Education System
To assess the effectory stage of aKIR-HLAeeducated NK
cells, we compared PFS and TTP in patients with and without
an HLA ligand cognate for aKIR involved in education in the
donor (3-level selection, see Methods). We found deeply
reduced PFS and increased relapse/progression rate among
patients with malignant diseases with the missing single
HLA ligand cognate with aKIR involved in NK cell education
in donors, compared with patients possessing all cognate
HLA ligands (100% versus 50.2%; HR, 3.25; 95% CI, 1.74 to
6.08; P ¼ .00022, Pcorr ¼ .00045; median time to event, 119
versus 286 days; and 33.3% versus 19.2%; HR, 3.82; 95% CI,
Figure 1. (continued).
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versus 284 days; for PFS and TTP, respectively) (Figure 4A,B).
The effect was similar if compared groups were restricted to
HLA-mismatched donor-recipient pairs (100% versus 48.5%;
HR, 3.45; 95% CI 1.67 to 7.13; P¼ .00083, Pcorr¼ .0017;median
time to event, 106.5 versus 381 days; and 37.5% versus 16.9%;
HR, 4.26; 95% CI, 1.14 to 15.90; P ¼ .031, Pcorr ¼ .061; median
time to event, 105 versus 372 days; for PFS and TTP, respec-
tively) (Table 3). These ﬁndings strongly suggest that the NK
cell anticancer function is abrogated if the HLA ligand
cognate with donor’s educating aKIR is missing in patients
with malignancy. The functionality of a missing education
ligand in patients seems to be independent of the level of
HLA mismatch itself. For cancer immunosurveillance, these
results may indicate that the education of NK cells by aKIR-
cognate HLA ligand pairs is as important as licensing via
iKIR-HLA ligand pairs and the lack of ligation of aKIRs
expressed speciﬁcally by educated NK cells can decompose
the immunosurveillance.
The incidence of grade II to IV aGVHD was similar in
patients deﬁcient with a single HLA ligand cognate with
any aKIR-HLAebased education system in donors, and
those sufﬁcient with all cognate HLA ligands (36.4% versus
30.2%; odds ratio [OR], 1.32; 95% CI, .37 to 4.68; P ¼ .67,
Pcorr ¼ .89; and 36.4% versus 39.1%; OR, .89; 95% CI, .24 to
3.36; P ¼ .87, Pcorr ¼ .98; for all donor-recipient pairs and
the subset of patients with HLA-mismatched donor,
respectively) (Table 4). The incidence of intermediate/high-
grade aGVHD seems to be independent of whether the
missing HLA ligand in patient was cognate or not with the
aKIR-HLAemediated NK cell education system in the
respective donor.DISCUSSION
To our knowledge, this is the ﬁrst study showing sys-
tematic clinical relevance of NK cell education via different
aKIRs and cognate HLA ligands in patients with malignant
diseases after HSCT. Coexpression of C1:KIR2DS2/3,
C2:KIR2DS1, and/or Bw4:KIR3DS1 aKIR-HLA pairs in donors
is functional in NK cell education, can implicate NK cell
hyporesponsiveness to malignant cells in the recipient, and
can worsen both survival and relapse/progression rate in
patients with malignancy after HSCT. These data are consis-
tent with education effects observed earlier for C2:KIR2DS1
axis, both in vitro and in the HSCT setting [15,23].
The NK cell education via aKIRs results in quantitative
effect where a higher number of aKIR-cognate HLA pairs in
donors implicates larger hyporesponsiveness to the re-
cipients’ malignant cells. This ﬁnding is in line with some of
the association studies in acute myeloid leukemia/myelo-
dysplastic syndrome patients who received transplants from
donors with a low number of aKIR genes or donors with KIR
group A haplotype, known to carry only 1 aKIR. In these
patients, a reduced relapse rate and improved disease-fee
survival were found [36,37]. Although these studies did not
consider NK cell education and were 1-level selection
association studies, the aKIR-based education was less
probable when the number of aKIR genes was low in the
donor. Due to the independent segregation of HLA and
KIR genes and preferential nonstochastic mode of aKIR
expression [38,39], it is likely that in the presence of multiple
aKIR-HLAebased education systems encoded in the donor,
multiple NK cell clones could be hyporesponsive to the
patient’s malignant cells, and relapse or progression can
occur more frequently.
Figure 2. Clinical outcome in transplant recipients with malignant diseases depending on the number of activating KIR-cognate HLA ligand NK cell education systems
in the donors. The cumulative PFS (left panel) and TTP (right panel) are shown for patients who received transplants from donors with (A,B) 0, 1, or 2 systems out of
C1:KIR2DS2/3 and C2:KIR2DS1 groups, and (C,D) 0, 1, 2, or 3 systems of C1:KIR2DS2/3, C2:KIR2DS1, and Bw4:KIR3DS1. Abbreviations are explained in Figure 1.
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different NK cell education systems, with strongest effect for
C1:KIR2DS2/3 and gradually weaker effect for C2:KIR2DS1,
Bw4:KIR3DS1, and A11/C2/4/5/16:KIR2DS4 systems. TheseFigure 3. Clinical outcome in transplant recipients with malignant diseases depen
KIR2DS2/3 education system or the lack (aKIR-HLAenull donors) of aKIR-mediated
in donor were excluded. (A) The cumulative PFS and (B) TTP in patients with single A1
deﬁcient for the education system (null donors). In these comparisons, patients who r
HLA-C*02, C*04, and C*05 molecules can ligate both KIR2DS4 and KIR2DS1 (the recep
based education systems. Patients who received transplants from HLA-C*16:01-posit
KIR2DS4 and KIR2DS2/3 (the receptors for group C1 ligands) and induce a partia
explained in Figure 1.data point to qualitative mode of aKIR-HLAemediated NK
cell education, as well. For qualitative functionality, it might
be important that different aKIR genes and their alleles
inherently show various NK cell expressions and afﬁnities toding on the presence of single positive (sp)A11/C2/4/5/16-KIR2DS4 or spC1-
NK cell education. Donor-recipient pairs with overlapping education systems
1/C2/4/5-KIR2DS4 NK cell education system in donors, single C1-KIR2DS2/3, or
eceived transplants from C2-KIR2DS1epositive donors were excluded because
tor for group C2 ligands) and induce a partial functional overlapping with C2-
ive donors were also excluded because HLA-C*16:01 molecule can ligate both
l functional overlapping with C1-based education system. Abbreviations are
Table 3
PFS and TTP in HSC Recipients with Malignant Diseases Depending on aKIR-Mediated NK Cell Education in Donor or Missing Ligand in Recipient Cognate with
Educating aKIR in Donor
aKIR-Based NK Cell Education Status n Education Dþ Education D() HR 95% CI P Value Pcorr
Events/n (%) median time to event, d
PFS
KIR2DS2/3 & C1 D(þ) versus KIR2DS2/3 & C1 D() 87 31/43 (72.1) 138 16/44 (36.4) 662 3.17 1.71-5.86 .00024 .00048
KIR2DS1 & C2 D(þ) versus KIR2DS1 & C2 D(þ) 87 17/22 (77.3) 261,5 30/65 (46.2) 356 2.03 1.11-3.69 .021 .042
KIR3DS1 & Bw4 D(þ) versus KIR3DS1 & Bw4 D() 87 18/23 (78.3) 349 29/64 (45.3) 352 1.89 1.05-3.42 .034 .067
KIR2DS4 & A11/C5/2/4/16 D(þ) versus
KIR2DS4 & A11/C5/2/4/16 D()
87 28/52 (53.8) 387 19/35 (54.3) 225 .84 .47-1.51 .57 .82
TTP
KIR2DS2/3 & C1 D(þ) versus KIR2DS2/3 & C1 D() 75 10/37 (27.0) 138 3/38 (7.9) 618.5 5.97 1.63-21.91 .0071 .014
KIR2DS1 & C2 D(þ) versus KIR2DS1 & C2 D(þ) 75 6/21 (28.6) 237 7/54 (13.0) 352.5 2.82 .94-8.46 .065 .13
KIR3DS1 & Bw4 D(þ) versus KIR3DS1 & Bw4 D() 75 5/21 (23.8) 349 8/54 (14.8) 292.5 1.73 .56-5.34 .34 .56
KIR2DS4 & A11/C5/2/4/16 D(þ) versus KIR2DS4
& A11/C5/2/4/16 D()
75 8/45 (17.8) 384 5/30 (16.7) 198.5 .85 .28-2.59 .77 .95
aKIR-Based NK Cell Education in Donor and Missing
Cognate Ligand in Recipient
Education Dþ; Lig R() Education Dþ; Lig R(þ)
PFS
aKIR Edu. D(þ) HLA ligand R() versus
aKIR Edu. D(þ) HLA Ligand R(þ)
78 10/10 (100) 106.5 33/68 (48.5) 381 3.45 1.67-7.13 .00083 .0017
TTP
aKIR Edu. D(þ) HLA Ligand R() versus
aKIR Edu. D(þ) HLA Ligand R(þ)
67 3/8 (37.5) 105 10/59 (16.9) 372 4.26 1.14-15.90 .031 .061
Dþ/D(), positive or negative status in donor, respectively; Rþ/R(), positive or negative status in recipient, respectively; aKIR Edu., denotes activating killer cell
immunoglobulin-like receptor-cognate HLA ligand education system.
Data restricted to HLA mismatched donor-recipient pairs. Comparisons were adjusted for patient’s age (lower inclusive, or higher than 18), diagnosis (lympho-
or myeloproliferative disease), level of risk (low or intermediate/high), and conditioning regimen (myeloablative or reduced intensity).
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of NK cell education was strong for C1:KIR2DS2/3,
C2:KIR2DS1, and Bw4:KIR3DS1 education systems in donors,
whereas the A11/C2/4/5/16:KIR2DS4 system showed negli-
gible biological impact. The explanation for this low educa-
tion functionality can stem from the relative frequency of
full-length and dysfunctional 22-del KIR2DS4 gene variants
with 17% and 63% gene frequencies, respectively, in ethni-
cally matched healthy population [31]. The product of
deleted variant of KIR2DS4 is not anchored to the cellTable 4
Incidence of Grade II to IV aGVHD in HSC Recipients with and without aKIR-HLA Liga
in Recipients
aKIR-Based NK Cell Education Status n aGVHD Inciden
Edu. D(þ) even
All pairs
KIR2DS2/3 & C1 D(þ) versus KIR2DS2/3 & C1 D() 262 36/125 (28.8)
KIR2DS1 & C2 D(þ) versus KIR2DS1 & C2 D(þ) 263 25/65 (38.5)
KIR3DS1 & Bw4 D(þ) versus KIR3DS1 & Bw4 D() 263 22/79 (27.8)
KIR2DS4 & A11/C5/2/4/16 D(þ) versus
KIR2DS4 & A11/C5/2/4/16 D()
263 37/127 (29.1)
Edu. D(þ)
Lig R()
aKIR Edu. D(þ) HLA Ligand R() versus
aKIR Edu. D(þ) HLA Ligand R(þ)
213 4/11 (36.4)
HLA mismatched pairs Edu. D(þ)
KIR2DS2/3 & C1 D(þ) versus KIR2DS2/3 & C1 D() 83 15/41 (36.6)
KIR2DS1 & C2 D(þ) versus KIR2DS1 & C2 D(þ) 83 10/20 (50.0)
KIR3DS1 & Bw4 D(þ) versus KIR3DS1 & Bw4 D() 83 9/22 (40.9)
KIR2DS4 & A11/C5/2/4/16 D(þ) versus
KIR2DS4 & A11/C5/2/4/16 D()
83 20/50 (40.0)
Edu. D(þ)
Lig R()
aKIR Edu. D(þ) HLA ligand R() versus
aKIR Edu. D(þ) HLA ligand R(þ)
75 4/11 (36.4)
Lig, cognate HLA ligand in recipient; aKIR Edu., activating killer cell immunoglobuli
coexpression of C1 and KIR2DS2/3, C2 and KIR2DS1, Bw4 and KIR3DS1 or A11/C2/4/5membrane but encodes a soluble form of the protein that is
potentially secreted [41]. It is likely that the shedding
phenomenon can eliminate the education capacity of
KIR2DS4-del molecule. It is also possible that non-HLA class
Iedependent activating receptors that are present in aKIR-
HLA-null donors and their stress-induced ligands (such as
NKG2D-MICA/B system and NKp30, NKp44, and/or NKp46 of
uncertain ligands) [42] are potentially functional in NK cell
education in patients with malignancy. This suggestion is in
line with the data that, in contrast to clonal expression ofnd-Dependent NKCell Education in Donors andMissing Cognate HLA Ligand
ce/n (%) OR 95% CI P Pcorr
ts/n (%) Edu. D() events/n (%)
42/137 (30.7) .91 .54-1.56 .74 .93
53/198 (26.8) 1.71 .95-3.10 .075 .14
56/184 (30.4) .88 .49-1.58 .67 .89
41/136 (30.1) .95 .56-1.62 .86 .98
Edu. D(þ)
Lig R(þ)
61/202 (30.2) 1.32 .37-4.68 .67 .89
Edu. D()
15/42 (35.7) 1.04 .42-2.54 .93 1.00
20/63 (31.7) 2.15 .77-5.10 .14 .26
21/61 (34.4) 1.32 .48-3.59 .59 .83
10/33 (30.3) 1.53 .60-3.90 .37 .60
Edu. D(þ)
Lig R(þ)
25/64 (39.1) .89 .24-3.36 .87 .98
n-like receptor-cognate HLA ligand education system in donor depending on
/19 and KIR2DS4 gene pairs. Further abbreviations are explained in Table 3.
Figure 4. Clinical outcome in transplant recipients with malignant diseases depending on the missing HLA ligand in patients cognate with activating KIR involved in
NK cell education in donor. (A) The cumulative PFS and (B) TTP are shown for patients with missing HLA ligand for C1:KIR2DS2/3, C2:KIR2DS1, or A11/C2/4/5/
16:KIR2DS4 NK cell education system in donors, compared with patients who were sufﬁcient with all corresponding HLA ligands. aKIR Edu., denotes activating KIR-
HLA ligand education system in donor; R(þ), positive in recipient; R(), negative in recipient. Further abbreviations are explained in Figure 1.
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common on nearly all NK cells in steady state conditions [43]
and upon tumor challenge can outweigh a weak aKIR-type
education function of A11/C2/4/5/16:KIR2DS4 system [44].
Furthermore, our ﬁndings suggest that the NK cell anti-
tumor function in HSCT setting strongly depends on the
presence of educating HLA ligand in recipient cells. Although
generally withstanding the Bonferroni correction, this set of
data is hindered by a small strata rendering the data on PFS
and TTP comparisons unsettled. We present them to show
some intriguing directions for further study. The effect of the
recipient’s missing ligand cognate with donor’s NK cell
clones educated via aKIR-HLA is strongly adverse and results
in lower PFS and shorter TTP. This observation contrasts with
the favorable role of the model “missing self” recognition
that involves the missing ligand for NK cell clones unselected
for their education status [17,45]. Our results may suggest the
dysregulation of the NK cellemediated cancer immuno-
surveillancewhen aKIR-HLAeeducated NK cells of transplant
origin can no longer be engaged by the cognate HLA ligand in
the recipient malignant cells. Although aKIR-HLAebased NK
cell education leads to hyporesponsiveness, the cognate-
educating HLA ligand of the cancer patient appears to be
involved in triggering the tumor-killing function in the
educated donor NK cells. This observation is in line with
in vitro data where patients’ HLA-C2 homozygous leukemia
blasts and Epstein-Barr virusetransformed B cell lines were
very efﬁciently killed by donor NK cell clones educated via
C2:KIR2DS1 [6]. The clone was cytolytic against the target
cells, and lysis was strongly inhibited by blocking KIR2DS1,
indicating a positive role of aKIR even in hyporesponsive,
educated NK cells. It seems likely that, compared with
uneducated NK cells, these NK cells educated via aKIRs
and cognate HLA may play a crucial role in cancer
immunosurveillance.
The adverse impact of the recipient’s missing HLA ligand,
the 1 cognate with donor’s aKIR, was similar to our previous
results for donor iKIRs [30], wherein we observed an adverse
impact of missing ligands in recipients cognate with an iKIR-
HLA licensing system in the donor. These 2 harmful receptor-
ligand constellations together can be explained by the
ﬁnding that multiple receptors have been implicated in the
cocreation of immunological synapses and close cooperation
in natural cytotoxicity. In immunological synapse, theinhibitory and activating KIR-HLA signaling is integrated
with additional components (eg, accessory molecules and
non-KIR inhibitory and activating receptors after engage-
ment by transformation-induced ligands) [46]. These mole-
cules with their ligands regulate 2 main effector functions of
NK cells: the adhesion to the target cell and the release of
cytotoxic granules. Although little is known about the
mechanism of NK cell education, it was shown that the
engagement of activating receptors with associated DAP-12
immunoreceptor by the cognate ligand induces the
increased NK cell conjugation to target cell due to the
elevated inside-out signaling from their immunoreceptor to
b2 integrin LFA-1 [20,47]. The adhesion to the target cell is
promoted by each activating receptor (and some accessory
molecules) separately, whereas the degranulation requires
synergistic activation through coengagement of several
activating receptors [48]. It is crucial that engaged iKIRs in
educated NK cells can efﬁciently inhibit the degranulation
and not inhibit the adhesion [48]. Therefore, it seems likely
that educating HLA I ligands cognate with aKIRs take part in
degranulation and those HLA cognate with licensing iKIRs
can increase the adhesion of licensed/educated NK cell to
cancer cells and stabilize the immunological synapse.
Consequently, the NK cell killer function can be impaired by
the lack of either activation or inhibitory HLA class I ligands
on target cancer cells. It is likely that, without iKIR-HLA
engagement, NK cells become “not licensed to kill” and
without aKIR-HLA engagement this operational defect does
not help different activating signals overcome the inhibition.
These functional pathways inherent in NK cells are likely to
be intensiﬁed in fully responsive licensed/educated NK cells
as they all depend on KIR-HLA ligation [20,21,48].
Although it is likely and biologically plausible that the iKIR
and aKIR systems described in our previous paper [30] and
here have independent inﬂuence on relapse-free survival, we
cannot deﬁnitely conﬁrm this independence for lost educa-
tion status because of highly limited and partly overlapping
strata. Further independent study will elucidate whether or
not the lost NK cell education mediated by the missing
recipient HLA ligand cognate with donor inhibitory and aKIR
education repertoire have independent impacts on outcome.
Interestingly, our comparisons in patients after HSCT
show similar incidence of grade II to IV acute GVHD for pa-
tients who received a transplant from donors with and
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aGVHD is independent of aKIR-based education status in a
donor. Along with the ﬁnding that the GVT effect was
quantitatively dependent on aKIR-based NK cell education,
these observations may offer insight into the dissection be-
tween the GVHD and GVT effects in HSCT therapy. However,
further study should be undertaken considering educated
and uneducated NK cell status before reaching a conclusion.
Taken together, our data complement the model of NK
cell education where iKIR-mediated NK cell reactivity is
upregulated [10,20] and aKIR-mediated education induces
hyporeactivity to tissues, and both are dependent on the
recognition of ubiquitously expressed self MHC class I. It is
essential that the 2 immune pathways of NK cell activation
and education/hyporeactivity intersect at the aKIR-HLA
interface, and activation of NK cell can be prevented by the
target cell expressing self HLA. Similar immune pathway
intersection is the case for inhibition and licensing/hyper-
responsiveness pathways at the iKIR-HLA interface [10].
Importantly, as demonstrated for the C2:KIR2DS1 axis, the
aKIR-based education reduces the responsiveness of NK cells
to stimulation with cellular targets, but not with cytokines
alone [23]. Apparently, the intrinsic cytolytic pathways are
potentially active and are kept silent in NK cells educated via
aKIR-HLA. This activation-inhibition-education crosstalk
creates a platform to tolerize the otherwise highly reactive
NK cells against normal cells expressing self HLA. Simulta-
neously, the tolerization to normal cells redirects NK cell
responsiveness to stressed or malignant cells, expressing
induced ligands for non-HLA speciﬁceactivating receptors
that are unlikely to be involved in NK cell education in the
steady state [49]. The discovery of the quantitative additive
function of aKIR-HLA systems in NK cell education is
consistent with the ﬁnding of a synergistic role of activating
receptors in NK cell immunological synapse [48] and war-
rants its important role in clinical transplantation.
In conclusion, upon engagement with cognate HLA li-
gands in the HSC donor, activating KIRs are involved in NK
cell education that quantitatively depends on the number of
aKIR-HLA systems and leads to hyporesponsiveness of NK
cells. In clinical HSCT, these data suggest supplemental
selection of fully HLA matched donors with lowest possible
number of those aKIRs involved in NK cell education. This
can be fulﬁlled by the 2-level-selection of those donors with
deﬁned aKIR-HLA based NK cell education status. In partially
mismatched donor-recipient pairs, avoiding the selection of
HSC donors with aKIR-mediated education status, especially
when cognate HLA ligand is missing in the recipient, is
advisable. To avoid these donors, 3-level-selection is neces-
sary. The modulation of aKIR-HLA-based immune response
can also be considered in different models of adoptive NK
cellebased cancer immunotherapy [50,51], as cancer
immunosurveillance greatly depends on the aKIR-
HLAemediated NK cell education.
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